EPS for Q BioMed Inc. (QBIO) Expected At $-0.29

June 13, 2018 - By Kurt Siggers

Q BioMed Inc. (OTCMKTS:QBIO) Logo

Analysts expect Q BioMed Inc. (OTCMKTS:QBIO) to report $-0.29 EPS on July, 18.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.29 EPS. After having $-0.17 EPS previously, Q BioMed Inc.’s analysts see 70.59 % EPS growth. The stock increased 0.29% or $0.01 during the last trading session, reaching $3.42. About 84,468 shares traded. Q BioMed Inc. (OTCMKTS:QBIO) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company has market cap of $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It currently has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.